LU90310I2 - Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti - Google Patents
Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en partiInfo
- Publication number
- LU90310I2 LU90310I2 LU90310C LU90310C LU90310I2 LU 90310 I2 LU90310 I2 LU 90310I2 LU 90310 C LU90310 C LU 90310C LU 90310 C LU90310 C LU 90310C LU 90310 I2 LU90310 I2 LU 90310I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- amino acid
- trovafloxacin
- pharmaceutically acceptable
- precursors
- prodrugs
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 125000000539 amino acid group Chemical group 0.000 title 3
- 239000002243 precursor Substances 0.000 title 2
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 title 2
- 229960000497 trovafloxacin Drugs 0.000 title 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title 1
- UUZPPAMZDFLUHD-VUJLHGSVSA-N alatrofloxacin Chemical compound C([C@@H]1[C@H]([C@@H]1C1)NC(=O)[C@H](C)NC(=O)[C@@H](N)C)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F UUZPPAMZDFLUHD-VUJLHGSVSA-N 0.000 title 1
- 229960000919 alatrofloxacin Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- -1 quinolone carboxylic acids Chemical class 0.000 abstract 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- 125000006519 CCH3 Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- AQIAIZBHFAKICS-UHFFFAOYSA-N methylaminomethyl Chemical compound [CH2]NC AQIAIZBHFAKICS-UHFFFAOYSA-N 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1989/003489 WO1991002526A1 (en) | 1989-08-16 | 1989-08-16 | Azabicyclo quinolone carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU90310I2 true LU90310I2 (fr) | 1999-01-25 |
Family
ID=22215165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU90310C LU90310I2 (fr) | 1989-08-16 | 1998-11-04 | Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti |
| LU90311C LU90311I2 (fr) | 1989-08-16 | 1998-11-04 | Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU90311C LU90311I2 (fr) | 1989-08-16 | 1998-11-04 | Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0413455B1 (pl) |
| JP (2) | JPH072734B2 (pl) |
| KR (1) | KR930004844B1 (pl) |
| CN (1) | CN1025192C (pl) |
| AT (1) | ATE124040T1 (pl) |
| AU (1) | AU623801B2 (pl) |
| BA (1) | BA98299A (pl) |
| CA (2) | CA2127561C (pl) |
| CY (2) | CY1969A (pl) |
| CZ (1) | CZ281127B6 (pl) |
| DD (1) | DD298399A5 (pl) |
| DE (3) | DE69020262T2 (pl) |
| DK (1) | DK0413455T3 (pl) |
| EG (1) | EG19251A (pl) |
| ES (1) | ES2074131T4 (pl) |
| FI (2) | FI108228B (pl) |
| GR (1) | GR3017072T3 (pl) |
| HU (2) | HU219403B (pl) |
| IE (1) | IE66202B1 (pl) |
| IL (1) | IL95331A (pl) |
| LU (2) | LU90310I2 (pl) |
| NL (2) | NL980033I2 (pl) |
| NO (1) | NO300214B1 (pl) |
| NZ (1) | NZ234920A (pl) |
| PL (1) | PL166381B1 (pl) |
| PT (1) | PT94998B (pl) |
| RU (1) | RU2049777C1 (pl) |
| WO (1) | WO1991002526A1 (pl) |
| ZA (1) | ZA906450B (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449445A3 (en) * | 1990-03-27 | 1993-08-25 | Pfizer Inc. | Preparation of beta-ketoesters useful in preparing quinolone antibiotics |
| FR2675144B1 (fr) * | 1991-04-10 | 1995-06-16 | Bouchara Sa | Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant. |
| ES2136086T3 (es) * | 1991-06-19 | 1999-11-16 | Pfizer | Agentes antibacterianos con azaespiroquinolona. |
| US5256791A (en) * | 1992-03-02 | 1993-10-26 | Pfizer Inc. | Preparation of intermediates in the synthesis of quinoline antibiotics |
| EG20543A (en) * | 1992-10-30 | 1999-07-31 | Procter & Gamble | Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones |
| US5527910A (en) * | 1992-12-30 | 1996-06-18 | Cheil Foods & Chemicals, Inc. | Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria |
| US5591766A (en) * | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
| ES2173175T3 (es) * | 1994-02-04 | 2002-10-16 | Dainippon Pharmaceutical Co | Derivado de acido piridonacarboxilico sustituido con un grupo amino biciclico, ester del mismo, sal del mismo, y amina biciclica como intermedio para su preparacion. |
| JPH08213881A (ja) * | 1995-02-02 | 1996-08-20 | Fujitsu Ltd | 周波数制御回路 |
| DK0807630T3 (da) * | 1995-02-02 | 2003-09-01 | Daiichi Seiyaku Co | Heterocykliske forbindelser |
| TW466237B (en) * | 1995-02-07 | 2001-12-01 | Daiichi Seiyaku Co | Heterocyclic spiro-derivative |
| DK0789697T3 (da) * | 1995-06-06 | 1998-10-19 | Pfizer | Krystalform af vandfrit 7-([1alfa, 5alfa, 6alfa,]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-fluor-1-(2,4-difluorphenyl)-1,4-d |
| WO1997000268A1 (en) * | 1995-06-15 | 1997-01-03 | Pfizer Inc. | Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide |
| PT882725E (pt) * | 1996-02-09 | 2003-04-30 | Toyama Chemical Co Ltd | Derivados do acido quinolonacarboxilico ou os seus sais |
| AP788A (en) * | 1996-08-26 | 1999-12-03 | Pfizer | Novel crystal form of anhydrous 7-(1a, 5a, 6a)-6-Amino-3-Azabicyclo(3.1.0) hex-3-YI)-6-Fluoro-1-(2,4- Difluorophenyl)-1,4-Dihydro-4-Oxo-1, 8-Naphthyridine-3-Carboxylic Acid, Methanesulfonic acid salt. |
| TW519542B (en) * | 1996-09-27 | 2003-02-01 | Daiichi Seiyaku Co | Bicyclic amine derivative |
| ATE267191T1 (de) * | 1996-10-25 | 2004-06-15 | Daiichi Seiyaku Co | Tricyclische aminderivate |
| MA24500A1 (fr) | 1997-03-21 | 1998-10-01 | Lg Life Sciences Ltd | Derive du sel d'acide carboxylique de naphthyridine . |
| US20020032216A1 (en) | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
| DE19733439A1 (de) * | 1997-08-02 | 1999-02-04 | Bayer Ag | Neue 6-endo-Amino-3-azabicyclo(3.1.0)hexande, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung von Chinolon- und Naphthyridincarbonsäure-Derviaten mit verbesserten Eigenschaften |
| PT1015445E (pt) | 1997-09-15 | 2009-05-14 | Procter & Gamble | Quinolonas antimicrobianas, suas composições e seus usos |
| US6184380B1 (en) * | 1999-01-25 | 2001-02-06 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
| PA8464701A1 (es) * | 1998-01-16 | 2000-09-29 | Pfizer Prod Inc | Procedimiento e intermedios para preparar naftiridonas |
| US7019142B2 (en) | 1998-01-16 | 2006-03-28 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
| GB9820405D0 (en) | 1998-09-18 | 1998-11-11 | Smithkline Beecham Plc | Process |
| EP1161956A4 (en) | 1999-03-17 | 2005-03-16 | Daiichi Seiyaku Co | DRUG COMPOSITIONS |
| GB9920919D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel compound |
| GB9920917D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel process |
| NZ525571A (en) | 2000-12-14 | 2004-09-24 | Procter & Gamble | Antimicrobial quinolones |
| IL155678A0 (en) | 2000-12-14 | 2003-11-23 | Procter & Gamble | Antimicrobial 2-pyridones, their compositions and uses |
| KR100517638B1 (ko) | 2002-04-08 | 2005-09-28 | 주식회사 엘지생명과학 | 게미플록사신 산염의 새로운 제조방법 |
| US7399779B2 (en) | 2002-07-08 | 2008-07-15 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists |
| ATE423769T1 (de) | 2002-08-23 | 2009-03-15 | Ranbaxy Lab Ltd | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten |
| US7517905B2 (en) | 2003-04-09 | 2009-04-14 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| BR0318242A (pt) | 2003-04-10 | 2006-04-04 | Ranbaxy Lab Ltd | derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação |
| US20070021487A1 (en) | 2003-04-11 | 2007-01-25 | Mohammad Salman | Azabicyclo derivatives as muscarinic receptor antagonists |
| KR101077755B1 (ko) | 2003-09-10 | 2011-10-27 | 교린 세이야꾸 가부시키 가이샤 | 7-(4-치환-3-시클로프로필아미노메틸-1-피롤리디닐)퀴놀론카르본산 유도체 |
| EP1670759A1 (en) * | 2003-09-18 | 2006-06-21 | Ranbaxy Laboratories Limited | PROCESS FOR THE PREPARATION OF (1a, 5a, 6a)-6-AMINOME THYL-3-BENZYL-3-AZABICYCLO 3.1.0 HEXANE |
| TWI391378B (zh) * | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| BRPI0709220A2 (pt) | 2006-03-28 | 2011-07-12 | Procter & Gamble | processo de acoplamento para preparo de intermediários de quinolona |
| SI2001862T1 (sl) | 2006-03-28 | 2011-10-28 | Warner Chilcott Co Llc | Soli malatov in polimorfi (3S, 5S)-7-(3-amino-5-metil-piperidinil)-1-ciklopropil-1,4-dihidro-8-metoksi- 4-okso-3-kinolinkarboksline kisline |
| US7902227B2 (en) * | 2007-07-27 | 2011-03-08 | Janssen Pharmaceutica Nv. | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents |
| US9133116B2 (en) | 2010-09-28 | 2015-09-15 | Panacea Biotec Ltd. | Bicyclic compounds |
| EP3856735B1 (en) * | 2018-10-05 | 2023-09-06 | New York University | Fused bicyclic heterocycles as therapeutic agents |
| CN112442084B (zh) * | 2020-12-03 | 2022-09-09 | 国药集团致君（深圳）制药有限公司 | 一种抗菌药中间体的制备方法 |
| CN113307768B (zh) * | 2021-04-29 | 2023-12-12 | 中国农业科学院兰州畜牧与兽药研究所 | 喹诺酮类衍生物及其制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0676400B2 (ja) * | 1987-08-25 | 1994-09-28 | 大日本製薬株式会社 | 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩 |
| JP2844079B2 (ja) * | 1988-05-23 | 1999-01-06 | 塩野義製薬株式会社 | ピリドンカルボン酸系抗菌剤 |
| US4973091A (en) * | 1989-09-20 | 1990-11-27 | Truth Incorporated | Sliding patio door dual point latch and lock |
-
1989
- 1989-08-16 IE IE295090A patent/IE66202B1/en not_active IP Right Cessation
- 1989-08-16 HU HU9200460A patent/HU219403B/hu not_active IP Right Cessation
- 1989-08-16 RU SU5011662/04A patent/RU2049777C1/ru not_active IP Right Cessation
- 1989-08-16 PL PL90286484A patent/PL166381B1/pl unknown
- 1989-08-16 WO PCT/US1989/003489 patent/WO1991002526A1/en not_active Ceased
-
1990
- 1990-07-30 DE DE69020262T patent/DE69020262T2/de not_active Expired - Fee Related
- 1990-07-30 EP EP90308331A patent/EP0413455B1/en not_active Expired - Lifetime
- 1990-07-30 DE DE19875052C patent/DE19875052I2/de active Active
- 1990-07-30 ES ES90308331T patent/ES2074131T4/es not_active Expired - Lifetime
- 1990-07-30 DK DK90308331.9T patent/DK0413455T3/da active
- 1990-07-30 DE DE19875050C patent/DE19875050I2/de active Active
- 1990-07-30 AT AT90308331T patent/ATE124040T1/de active
- 1990-08-09 IL IL9533190A patent/IL95331A/en not_active IP Right Cessation
- 1990-08-14 CA CA002127561A patent/CA2127561C/en not_active Expired - Lifetime
- 1990-08-14 EG EG48390A patent/EG19251A/xx active
- 1990-08-14 KR KR1019900012528A patent/KR930004844B1/ko not_active Expired - Fee Related
- 1990-08-14 CA CA002023217A patent/CA2023217C/en not_active Expired - Lifetime
- 1990-08-14 PT PT94998A patent/PT94998B/pt not_active IP Right Cessation
- 1990-08-15 NZ NZ234920A patent/NZ234920A/en unknown
- 1990-08-15 DD DD90343474A patent/DD298399A5/de unknown
- 1990-08-15 ZA ZA906450A patent/ZA906450B/xx unknown
- 1990-08-15 CN CN90106794A patent/CN1025192C/zh not_active Expired - Fee Related
- 1990-08-15 AU AU61042/90A patent/AU623801B2/en not_active Expired
- 1990-08-16 JP JP2216461A patent/JPH072734B2/ja not_active Expired - Fee Related
- 1990-08-16 CZ CS904027A patent/CZ281127B6/cs not_active IP Right Cessation
-
1992
- 1992-02-14 FI FI920632A patent/FI108228B/fi active Protection Beyond IP Right Term
- 1992-02-14 NO NO920599A patent/NO300214B1/no not_active IP Right Cessation
-
1994
- 1994-07-08 JP JP6157008A patent/JPH0819099B2/ja not_active Expired - Fee Related
-
1995
- 1995-06-22 HU HU95P/P00380P patent/HU211681A9/hu unknown
- 1995-08-09 GR GR950402200T patent/GR3017072T3/el unknown
-
1996
- 1996-11-11 FI FI964520A patent/FI103879B/fi active
-
1997
- 1997-09-05 CY CY196997A patent/CY1969A/xx unknown
-
1998
- 1998-03-30 BA BA980299A patent/BA98299A/bs unknown
- 1998-11-04 LU LU90310C patent/LU90310I2/xx unknown
- 1998-11-04 LU LU90311C patent/LU90311I2/xx unknown
- 1998-11-17 NL NL980033C patent/NL980033I2/nl unknown
- 1998-11-17 NL NL980032C patent/NL980032I2/nl unknown
-
1999
- 1999-05-24 CY CY1999010C patent/CY99010I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU90310I2 (fr) | Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti | |
| AR012588A1 (es) | UN INHIBIDOR DE SERINA PROTEASA, UNA COMPOSICIoN FARMACEUTICA QUE LO COMPRENDE Y UN PROCEDIMIENTO PARA PREPARAR UNA COMPOSICIoN FARMACEUTICA | |
| RU2000111540A (ru) | Агонисты аполипопротеина а-1 и их применение для лечения заболеваний, связанных с дислипидемией | |
| JP2002509910A5 (pl) | ||
| KR970042553A (ko) | 캠프토테신 유도체 | |
| ATE293453T1 (de) | Verbindungen zur behandlung von sexuellen funktionsstörungen | |
| ES8105698A1 (es) | Procedimiento para la obtencion de octapeptidos ciclicos | |
| EE02950B1 (et) | Metüleenbisfosfoonhappe esteramiidderivaadid, meetod nende valmistamiseks ja farmatseutiline kompositsioon | |
| KR900009692A (ko) | 레트로바이러스 프로테아제 억제제 | |
| UA74421C2 (uk) | Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування | |
| EP1181933A3 (en) | Use of growth hormone secretagogues for stimulating or increasing appetite | |
| JPH09124692A5 (pl) | ||
| JPH07509215A (ja) | ジヒドロ葉酸還元酵素の特異的阻害およびそのための化合物 | |
| EP0346068A3 (en) | D-cys6 vasopressin antagonists | |
| HUT59919A (en) | Process for producing azabicyclo-quinolon and naphtiridone derivatives and pharmaceutical compositions containing them | |
| WO1994004565A3 (en) | Ipnv vaccine | |
| US6218364B1 (en) | Fluorinated neurokinin A antagonists | |
| ES2005778A6 (es) | Procedimiento para la obtencion de derivados de diisobutilxantina. | |
| RU98117609A (ru) | Пептидные производные | |
| RU99100332A (ru) | Производные пептидов |